BIIB - These Analysts Revise Their Forecasts On Biogen After Q3 Results | Benzinga
Biogen Inc (NASDAQ: BIIB) reported better-than-expected third-quarter earnings.
Biogen posted quarterly sales of $2.53 billion, beating the consensus of $2.39 billion, up 1% Y/Y and 3% at constant currency (CC). Adjusted EPS of $4.36, down 9%, beating the consensus of $3.97.
Biogen revised its FY23 revenues to decline in a low-single-digit percentage versus FY22 compared to earlier guidance of a mid-single-digit percentage decline.
Biogen shares fell 3.2% to trade at ...